Q3FY17 Results : Marksans Pharma

Bhagyashree Vivarekar / 06 Feb 2017

Q3FY17 Results : Marksans Pharma

The company’s sales for Q3FY17 were Rs 215.2 crore, which represents a 15.02 per cent sequential increase and 1.06 per cent YoY decline.

Marksans Pharma Ltd. reported its consolidated results for the quarter ended December 31, 2016 today. 

The company’s sales for Q3FY17 were Rs 215.2 crore, which represents a 15.02 per cent sequential increase and 1.06 per cent YoY decline.

Its operating profit (EBIT) for the quarter was Rs 17 crore and its EBIT margin was 7.9 per cent.

The company's PAT for the quarter was Rs 12.8 crore, which represents a sequential QoQ increase of 3100 per cent and a YoY decline of 31.18 per cent.

Marksans Pharma Ltd is a pharmaceutical company with presence across the value chain from active pharmaceuticals ingredients (APIs) to formulations to biopharmaceuticals. The company's drugs span the fields of oncology, gastroenterology, antidiabetic, cardiovascular, pain management, gynaecology and others. The company is engaged in a single business segment, viz. manufacturing and marketing of pharmaceutical formulations.

If you want to stay updated with the share market news today, keep a close watch on the indian stock market today with real time movements like sensex today live and overall stock market today trends. Investors tracking ipo allotment status, ipo news today, or the latest ipo india can also follow daily updates along with bse share price live data. Whether you are learning how to invest in stock market in india, preparing for a market crash today, or searching for the best stocks to buy in india, insights on top gainers today india, top losers today india, trending stocks india and long term stocks india help in making informed investment decisions.